FDA approves breakthrough cholesterol pill with powerful LDL-lowering effect

Millions of Americans with high cholesterol now have a new treatment option, as the FDA has approved the first once-daily oral PCSK9 inhibitor. Merck, the New Jersey-based manufacturer of Lipfendra (enlicitide), announced the approval on Thursday.

Millions of Americans with high cholesterol now have a new treatment option, as the FDA has approved the first once-daily oral PCSK9 inhibitor. Merck, the New Jersey-based manufacturer of Lipfendra (enlicitide), announced the approval on Thursday.